Recombinant human IL-2 (rhIL-2) is now rarely used to treat patients with cancer because it too often causes severe toxicities. In this issue, Nirschl and colleagues report the development and preclinical characterization of an engineered IL-2 prodrug called WTX-124 that activates in the tumor microenvironment and has minimal systemic toxicity. It will be intriguing to watch the translation of this approach to the clinic.

See related article by Nirschl et al., p. 581 (5).

You do not currently have access to this content.